logo-loader

New use for foralumab in CAR T-cell therapy

Last updated: 09:09 06 Sep 2021 BST, First published: 07:09 06 Sep 2021 BST

Tiziana has a fully human therapeutic monoclonal antibody, foralumab, currently being developed for nasal, inhaled and oral delivery to treat autoimmune disease and COVID-19; it is the only fully human anti-CD3 monoclonal. Precision Biosciences, Tiziana’s new US partner, is developing “off-the-shelf” (allogeneic) CAR T-cell therapies. CAR T-cell therapy is a powerful new therapy type used for some blood cancers. To make it work, existing T-cells in patients need to be depleted first. This is done using highly toxic chemotherapy agents. The hypothesis being explored is to use foralumab to reduce or replace this chemotherapy in order to achieve a safer treatment regimen and enable more patients to access effective allogeneic CAR T-cell therapy.

 

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities,...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences Ltd named herein, including the promotion by the Company of Tiziana Life Sciences...

FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:

This document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.

Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO

FOR OUR FULL DISCLAIMER CLICK HERE

Proactive Analyst expects "some good news over the next 1-2 months" from...

Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant...

on 28/7/23